Epigallocatechin-3-O-gallate alleviates the malignant phenotype in A-431 epidermoid and SK-BR-3 breast cancer cell lines

Alexandru Filippi, Tiphanie Picot, Carmen Mariana Aanei, Péter Nagy, J. Szöllősi, Lydia Campos, Constanţa Ganea, Maria Magdalena Mocanu

Research output: Contribution to journalArticle

2 Citations (Scopus)


In this study, we evaluated the effects of epigallocatechin-3-O-gallate (EGCG) in two cancer cell lines, A-431 overexpressing ErbB1 and SK-BR-3, overexpressing ErbB2. EGCG treatment showed dose-dependent collapse of mitochondrial membrane potential (Δψm), increase in reactive oxygen species (ROS) production, changes in nuclear morphology and reduced viability. Flow cytometry data indicated that EGCG partially decreases the phosphorylation of several proteins involved in cell proliferation and survival: pErbB1(Y1173, Y1068), pAkt(S473) and pERK(Y204). EGCG affected the clonogenic growth in both cell lines with an EC50 of 2.5 and 5.4 µM for A-431 and SK-BR-3, respectively. Wound scratch assay demonstrated that EGCG inhibited the healing in dose-dependent manner and the effect was correlated with partial reduction in phosphorylation of pFAK(S910). Our data suggest that EGCG administration might reduce the unfavourable traits, particularly associated with ErbB1/EGFR overexpression.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalInternational Journal of Food Sciences and Nutrition
Publication statusAccepted/In press - Nov 21 2017



  • cancer
  • Epigallocatechin-3-O-gallate
  • mitochondrial membrane potential
  • ROS
  • signalling pathways

ASJC Scopus subject areas

  • Food Science

Cite this